Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to -$2.5 million.

  • Krystal Biotech's Change in Receivables fell 13345.42% to -$2.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $22.1 million, marking a year-over-year decrease of 6471.79%. This contributed to the annual value of $22.1 million for FY2025, which is 6471.79% down from last year.
  • Latest data reveals that Krystal Biotech reported Change in Receivables of -$2.5 million as of Q4 2025, which was down 13345.42% from $17.9 million recorded in Q3 2025.
  • Krystal Biotech's Change in Receivables' 5-year high stood at $56.8 million during Q2 2024, with a 5-year trough of -$5.9 million in Q3 2024.
  • For the 3-year period, Krystal Biotech's Change in Receivables averaged around $12.7 million, with its median value being $7.8 million (2024).
  • As far as peak fluctuations go, Krystal Biotech's Change in Receivables tumbled by 16375.05% in 2024, and later surged by 40178.48% in 2025.
  • Over the past 3 years, Krystal Biotech's Change in Receivables (Quarter) stood at $32.7 million in 2023, then plummeted by 77.24% to $7.4 million in 2024, then tumbled by 133.45% to -$2.5 million in 2025.
  • Its Change in Receivables was -$2.5 million in Q4 2025, compared to $17.9 million in Q3 2025 and $8.2 million in Q2 2025.